Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E

2012 ◽  
Vol 55 (3) ◽  
pp. 1082-1105 ◽  
Author(s):  
Martin W. Rowbottom ◽  
Raffaella Faraoni ◽  
Qi Chao ◽  
Brian T. Campbell ◽  
Andiliy G. Lai ◽  
...  
Keyword(s):  
Braf V600e ◽  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

2009 ◽  
Vol 52 (8) ◽  
pp. 2255-2264 ◽  
Author(s):  
Dan Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Ion Niculescu-Duvaz ◽  
Alfonso Zambon ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

scholarly journals Corrections to Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

2009 ◽  
Vol 52 (18) ◽  
pp. 5770-5770
Author(s):  
Dan Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Ion Niculescu-Duvaz ◽  
Alfonso Zambon ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group

2010 ◽  
Vol 53 (7) ◽  
pp. 2741-2756 ◽  
Author(s):  
Bart M. J. M. Suijkerbuijk ◽  
Ion Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Dan Niculescu-Duvaz ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

A2.31 Braf (v raf murine sarcoma viral oncogene homologue B1) mutations in rheumatoid arthritis patients

2015 ◽  
Vol 74 (Suppl 1) ◽  
pp. A28.2-A29
Author(s):  
F Arnoux ◽  
N Lambert ◽  
F Fina ◽  
M Martin ◽  
S Kanaan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold

2008 ◽  
Vol 51 (11) ◽  
pp. 3261-3274 ◽  
Author(s):  
Ion Niculescu-Duvaz ◽  
Esteban Roman ◽  
Steven R. Whittaker ◽  
Frank Friedlos ◽  
Ruth Kirk ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

A1.47 BRAF (v raf murine sarcoma viral oncogene homologue B1) mutations in rheumatoid arthritis patients

2014 ◽  
Vol 73 (Suppl 1) ◽  
pp. A20.1-A20
Author(s):  
Fanny Arnoux ◽  
Nathalie Lambert ◽  
Marielle Martin ◽  
Sami B. Kanaan ◽  
Nathalie Balandraud ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

scholarly journals Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

2017 ◽  
Vol 9 (7) ◽  
pp. 481-492 ◽  
Author(s):  
Amélie Boespflug ◽  
Julie Caramel ◽  
Stephane Dalle ◽  
Luc Thomas
Keyword(s):  
Metastatic Melanoma ◽  
Cytotoxic Chemotherapy ◽  
Disease Course ◽  
Line Treatment ◽  
First Line ◽  
Viral Oncogene ◽  
Melanoma Patients ◽  
Murine Sarcoma ◽  
Review Current ◽  
Viral Oncogene Homolog

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma.

Sign in / Sign up

Export Citation Format

Share Document